Urol. praxi, 2012; 13(4): 154-158

Densitometry of urological diseases

MUDr.Petr Hrdý, MUDr.Pavel Novosad
MEDIEKOS Labor s. r. o., Osteocentrum, Zlín

Densitometry is a radiologic imaging method determined bone mineral density (BMD) and bone mineral content (BMC). Vertebral bodies

L1 – L4 in anterioposterior projection and proximal femur in the area of neck (NECK) and globally (TOTAL) is measured according to osteological

standards. Diagnosis of osteoporosis is established in accordance with measurement of BMD abnormalities from average values at

young healthy individuals, the deviation sets as so-called T-score. Among most frequent causes of osteoporosis in urological ambulance

patients belong to hypogonadism and androgen deprived therapy for prostate cancer. There are still basic suplementation of calcium

and vitamin D in the prevention of osteoporosis, bisphosphonates are first choice medicine in the therapy of men osteoporosis.

Keywords: densitometry, BMD, T-score, osteoporosis, hypogonadism, androgen deprived therapy, bisphosphonates

Published: August 1, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Hrdý P, Novosad P. Densitometry of urological diseases. Urol. praxi. 2012;13(4):154-158.
Download citation

References

  1. Vyskočil V. Osteoporóza a ostatní nejčastější metabolická onemocnění skeletu. Praha: Galén 2009: 52.
  2. Official positions of the International Society for Clinical Densitometry. J Clin Densitom 2004; 7: 1-5.
  3. O´Neill TW. Incidence of vertebral fracture in Europe: results from the European Prospective Osteoporosis Study (EPOS). J Bone Miner Res 2002; 17: 716. Go to original source... Go to PubMed...
  4. Orwoll ES. Osteoporosis in Men. In: Rosen CJ, et al. Primer on the Metabolit Bone Diseases and Disorders of Mineral Metabolism. ASBMR: 2008: 287. Go to original source...
  5. Sharifi N. Androgen deprivation therapy for prostate cancer. JAMA 2005; 294: 238-244. Go to original source... Go to PubMed...
  6. Shahinian VB. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005; 352: 154-164. Go to original source... Go to PubMed...
  7. Hussain SA. Immediate dual energy X-ray absorptiometry reveals a high incidence of osteoporosis in patients with advanced prostate cancer before hormonal manipulation. BJU Int, 2003; 92: 690-694. Go to original source... Go to PubMed...
  8. Morote J. Bone mineral density changes in patients with prostate cancer during the first 2 years of androgen suppression, J Urol, 2006; 175: 1679-83; discussion 1683. Go to original source... Go to PubMed...
  9. Smith MR. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009; 361: 745-755. Go to original source... Go to PubMed...
  10. Souhrn údajů o přípravku, ,Prolia", 2 s. Dostupný na www. sukl.cz.




Urology for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.